High frequency oscillations (HFOs) as a unique pattern of EEG in a patient with anti-NMDA receptor encephalitis.

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).

Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practices.

Extended interval dosing of natalizumab in multiple sclerosis.

Neurological involvement and characterization in acquired hemophagocytic lymphohistiocytosis in adulthood.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Bilateral hearing loss as a manifestation of neuromyelitis optica.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus study.

Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus study.

Intrathecal baclofen in multiple sclerosis: too little, too late?

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.